197A.T
TAUNS Laboratories,Inc.
スタンダード · 医薬品 · 医薬品 · JP
JPY 501.00
−0.99%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +39.2%
- EBITDA
- —
- EPS
- +135.5%
Three-year CAGR
- Revenue
- +1.0%
- EBITDA
- +3.2%
- EBIT
- +2.9%
- Net income
- +9.4%
- EPS
- +7.5%
- Free cash flow
- -65.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026